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Introduction: There is argument over the benefits and risks of drugs for treating chronic musculoskeletal pain. This
study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for
patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA).
Methods: A systematic literature review used Medline and EMBASE to identify randomised controlled trials. Efficacy
outcomes assessed included: pain relief measured by visual analogue scale (VAS); Western Ontario McMaster Universities
Arthritis Index (WOMAC) VAS or WOMAC Likert scale; physical functioning measured by WOMAC VAS or Likert scale; and
patient global assessment (PGA) of disease severity measured on VAS or 5-point Likert scale. Safety outcomes included:
Antiplatelet Trialists’ Collaboration (APTC), major cardiovascular (CV) and major upper gastrointestinal (GI) events, and
withdrawals. Data for each outcome were synthesized by a Bayesian network meta-analysis (NMA). For efficacy
assessments, labelled doses for OA treatment were used for the base case while labelled doses for RA treatment
were also included in the sensitivity analysis. Pooled data across dose ranges were used for safety.
Results: Efficacy, safety, and tolerability data were found for 146,524 patients in 176 studies included in the NMA.
Diclofenac (150 mg/day) was likely to be more effective in alleviating pain than celecoxib (200 mg/day), naproxen
(1000 mg/day), and ibuprofen (2400 mg/day), and similar to etoricoxib (60 mg/day); a lower dose of diclofenac
(100 mg/day) was comparable to all other treatments in alleviating pain. Improved physical function with diclofenac
(100 and 150 mg/day) was mostly comparable to all other treatments. PGA with diclofenac (100 and 150 mg/day) was
likely to be more effective or comparable to all other treatments. All active treatments were similar for APTC and major
CV events. Major upper GI events with diclofenac were lower compared to naproxen and ibuprofen, comparable to
celecoxib, and higher than etoricoxib. Risk of withdrawal with diclofenac was lower compared to ibuprofen, similar to
celecoxib and naproxen, and higher than etoricoxib.
Conclusions: The benefit-risk profile of diclofenac was comparable to other treatments used for pain relief in OA and
RA; benefits and risks vary in individuals and need consideration when making treatment decisions.* Correspondence: akarabis@mapigroup.com
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Osteoarthritis (OA) and rheumatoid arthritis (RA) are
the most common arthritic conditions in adults [1]. Both
diseases lead to joint degeneration, are extremely painful,
and cause disability and a reduced quality of life [2,3],
resulting in a substantial burden to society [4,5].
More than 1.5 billion people worldwide suffer from
chronic pain, and arthritic conditions are one of the pri-
mary sources for chronic pain. Its prevalence is increas-
ing with an ageing population and pain management is
a global public health priority [6,7]. Pain also has mul-
tiple serious sequelae, including depression, inability to
work, disrupted social relationships, and even suicidal
thoughts [7]. Chronic pain and musculoskeletal disor-
ders are associated with some of the poorest health-
related quality of life (HRQoL) states ahead of neuro-
logical, renal, and cardiovascular (CV) diseases. Pa-
tients with pain have a greatly diminished HRQoL, with
severe restrictions on their functioning, work, and or-
dinary activities of daily living [8].
Good pain relief is what patients require from treatment,
and this comes with improvement in associated symptoms,
function, and quality of life [8,9]. Non-steroidal anti-
inflammatory drugs (NSAIDs), both traditional NSAIDs
(tNSAIDs) and cyclooxygenase 2 inhibitors (COXIBs) are
commonly prescribed to relieve patients from pain and in-
flammation [2,3]. NSAIDs, both oral and topical, are highly
effective analgesics that offer an array of meaningful and
differentiated benefits in alleviating pain, and are one of
the cornerstones for treating pain in arthritis patients
[10,11]. Several pooled analyses and meta-analyses combin-
ing randomised trials to estimate the efficacy of an NSAID
of interest have been performed [12-16].
In 2004, rofecoxib was withdrawn from the worldwide
market due to an increased risk in CV events during
chronic use [17]. Since then, the arterial thrombotic risk
associated with all NSAIDs, both tNSAIDs and COXIBs,
has been subjected to extensive review by medicines reg-
ulators, marketing authorization holders, and academic
groups around the world [17,18]. Many reviews and
(network) meta-analyses have been conducted to investi-
gate safety issues [19-21]. The Coxib and traditional
NSAID Trialists’ (CNT) Collaboration has performed
meta-analyses on vascular and upper gastrointestinal (GI)
effects of NSAIDs. The authors concluded that the vascu-
lar risk of high-dose diclofenac, and possibly ibuprofen,
are comparable to COXIBs, whereas high-dose naproxen
is associated with less vascular risk than other NSAIDs.
Additionally, the risk of upper GI complications, especially
bleeds, was increased compared to placebo for all COXIBs
and tNSAIDs [21].
These meta-analyses have focused mostly on the safety
and only a few assessed the efficacy of NSAIDs. None
have examined efficacy and safety together. Focusingsolely on risks and safety without addressing beneficial
effects or investigating only efficacy in the absence of a
risk and safety assessment fails to provide a holistic
picture of the comparative benefit-risk assessment of
NSAIDs. Regulators are also developing and testing tools
and processes for balancing multiple benefits and risks
as an aid to informed regulatory decisions about
benefit-risk assessment of medicinal products [22]. A
large number of randomised controlled trials (RCTs)
comparing efficacy and safety of NSAIDs to placebo or
to each other (head-to-head) exist, and data synthesis
methods can be used to combine them into an overall
assessment of efficacy and safety.
The objective of this study was to compare the effi-
cacy, safety, and tolerability of commonly used tNSAIDs
(diclofenac, ibuprofen, and naproxen) and COXIBs (cel-
ecoxib and etoricoxib) in patients with pain caused by
OA or RA by means of a Bayesian network meta-analysis
(NMA) [23-25]. This study is novel in that a range of differ-
ent key outcomes were brought together, including efficacy
(relief of pain, physical functioning, patient global assess-
ment (PGA)), tolerability (withdrawals), and safety (CV, GI)
associated with these treatments in arthritis patients.
Methods
The Benefit-Risk Action Team, a descriptive framework
to conduct benefit-risk assessment, has been followed for
structuring and presenting the results of this study [26,27].
The framework provides guidelines on organizing, under-
standing, and summarizing evidence of benefits and risks
into tabular outputs and graphical summaries to allow
comparison among treatments.
Decision context and benefit-risk outcomes identification
The decision context and the scope of the benefit-risk
assessment with respect to the population, intervention,
comparators, outcomes, and study design (PICOS) were
as follows:
Population: adult patients (≥18 years old) with OA or RA.
Intervention (Efficacy): diclofenac 75 to 150 mg/day,
naproxen 500 to 1,000 mg/day, ibuprofen 1,200 to
2,400 mg/day, celecoxib 100 to 400 mg/day, or
etoricoxib 30 to 90 mg/day.
Intervention (Safety and tolerability): diclofenac 75 to
200 mg/day, naproxen 500 to 1,500 mg/day, ibuprofen
1,200 to 2,400 mg/day, celecoxib 100 to 800 mg/day, or
etoricoxib 30 to 90 mg/day.
Comparators: any of the interventions above compared
to each other, placebo, or acetaminophen 4,000 mg/day.
Efficacy outcomes (Key benefits): pain relief measured
by visual analogue scale (VAS), Western Ontario
McMaster Universities Arthritis Index (WOMAC)
VAS, or WOMAC Likert scale; physical functioning
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PGA of disease severity measured on a VAS or 5-point
Likert scale; all outcomes reported at 6 or 12 weeks,
within a 2-week range.
Safety and tolerability outcomes (Key risks):
Antiplatelet Trialists’ Collaboration (APTC) events
(fatal and non-fatal myocardial infarction (MI) fatal and
non-fatal stroke, and other fatal CV events); major CV
events (stroke, MI, peripheral arterial thrombosis,
peripheral venous thrombosis, pulmonary embolism, and
CV-related death); major upper GI events (perforation,
obstruction, and gastric and/or duodenal ulcer (includes
bleeding ulcers)); withdrawal due to any cause, due to
lack of efficacy, or due to adverse events, as reported at
the longest follow-up time point.
Study design: RCTs with study duration ≥2 weeks for
efficacy outcomes and ≥4 weeks for safety and
tolerability outcomes.
A value tree was used to organize the key benefits and
risks included in the assessment and drove the benefit-
risk balance (Figure 1).
Identification and collection of source data
The MEDLINE, EMBASE, and Cochrane Library were
searched in June 2013 using predefined search strategies
(available in Additional file 1). Intervention and study
design terms were used, while a search filter was applied
to retrieve RCTs [28]. Abstracts and full text articles in a
language other than English were excluded.
The relevance of each citation identified was assessed
in a two-tiered approach. First, the titles and abstracts
were screened for eligibility, and those fulfilling the se-
lection criteria were included in the next stage. The fullFigure 1 Benefit-risk value tree.texts of the selected articles were retrieved and assessed.
Those that met the inclusion criteria were included for
data extraction. The assessment of each citation was per-
formed by one researcher (AvW) and checked against
the original study by another (PG). Any disagreement
was resolved by consensus or a third reviewer (AK).
Study and patient characteristics as well as efficacy,
safety, and tolerability outcomes from the selected stud-
ies were collected in a predesigned data extraction form.
Details on study characteristics were extracted, including
design; selection criteria; compared interventions; trial
duration; number of randomised and intention-to-treat
(ITT) patients; and allowance of gastro-protective agents,
aspirin, and rescue medication use. Additionally, baseline
patient characteristics were extracted, including age, gen-
der, disease duration, history of hypertension and GI ulcer,
and percentage of smokers.
For each continuous outcome of interest, the change
from baseline (CFB) and the associated sampling vari-
ance were extracted. If not available, CFB and standard
error were calculated based on the available data
(Additional file 2). If necessary, standardized mean dif-
ferences were calculated as the difference in CFB (ΔCFB)
between two interventions divided by the corresponding
standard deviation [29]. For dichotomous outcomes, the
number of patients experiencing an event was extracted
or estimated based on reported percentages and ITT
population. Subsequently, the total patient years (pyrs)
of follow-up were calculated. Data presented in graphs
were extracted using DigitizeIT version 1.5 software
(DigitizeIT, Braunschweig, Germany).
The methodological and reporting quality of the in-
cluded trials was assessed with the Oxford quality scor-
ing system for RCTs [30]. The risk of bias was assessed
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appropriate method, allocation concealment of patients
and investigators, and complete and non-selective
reporting of study withdrawals and dropouts.
Data synthesis
The selected benefit and risk outcomes, that is, relative
efficacy, safety, and tolerability of the treatments of
interest were evaluated using a Bayesian NMA [23-25].
Analyses within the Bayesian framework involve data, a
likelihood distribution, a model with parameters, and
prior distributions for these parameters. In this analysis,
a linear model with normal likelihood distribution was
used for continuous outcomes and a Poisson likelihood
with a log link was used for the dichotomous outcomes
[31,32]. Flat (non-informative) prior distributions were
assumed for all outcomes. Prior distributions of the rela-
tive treatment effects were normal, with zero mean and
variance of 10,000, while a uniform distribution with
range zero to five was used as the prior of the between-
study standard deviation.
It can be expected that there is always some variation
in patient characteristics, study sites, and settings across
studies. If these characteristics are effect modifiers of the
relative treatment effects of interest, there will be het-
erogeneity in the evidence base [25,33,34]. To allow for
heterogeneity between studies, random effects models
were evaluated. Random effects models assume that
treatment effects may vary between studies, but come
from a common distribution of treatment effects, with a
mean for each treatment effect and a common between-
study covariance matrix.
Furthermore, to address potential bias in our study, a
number of scenario analyses were defined a priori, while
for safety and tolerability only outcomes with at least 50
events reported in total per intervention (across all stud-
ies in the network) were analysed. This was done be-
cause a low number of events limits the ability of a
meta-analysis to detect differences between treatments
and can eventually give misleading results [35,36].
For each outcome, fixed and random effects models
were evaluated, and the better fitting model was selected
based on the lower Deviance Information Criterion value
[31]. The posterior densities for unknown parameters
were estimated using Markov chain Monte Carlo
(MCMC) simulations. All results were based on 80,000
iterations on three chains, with a burn-in of 20,000 itera-
tions. Convergence was assessed by visual inspection of
trace plots. The accuracy of the posterior estimates was
assessed using the Monte Carlo error for each parameter
(Monte Carlo error <1% of the posterior standard devi-
ation). All models were implemented using the Win-
BUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge,
UK) and were based on those defined by Dias et al. [32].The Bayesian NMA provided posterior distributions of
the relative treatment effects between interventions and
the probability that one treatment is better than another
for each outcome of interest. This probability is calcu-
lated based on the proportion of MCMC cycles in which
the specific treatment estimate is better than the com-
parator [32]. The results of the NMA are presented in
terms of ‘point estimates’ (median of posterior) for the
relative treatment effects, along with the 95% credible
intervals (95% CrI).
The efficacy outcomes are presented as ΔCFB, with
negative values indicating symptomatic improvement of
diclofenac relative to comparator. Safety and tolerability
results are presented as rate ratios (RR), with RR <1 in-
dicating that diclofenac is associated with a lower risk
relative to comparator.
Based on the relative treatment effects resulting from
the NMA, a treatment was considered as ‘more effective’
if the point estimate suggested the treatment is expected
to be better than the comparator and the 95% CrI does
not include 0 (for continuous outcomes) or 1 (for bin-
ary outcomes); ‘likely to be favourable’ if the 95% CrI
includes 0 or 1 but the point estimate is favourable and
there is a ≥85% probability that treatment is better
than the comparator; ‘comparable’ if the 95% CrI in-
cludes 0 or 1 (probability treatment is better than com-
parator >15% and <85%); ‘likely to be unfavourable’ if
the 95% CrI includes 0 or 1 but the point estimate is
unfavourable and there is a ≤15% probability that treat-
ment is better than the comparator; ‘less effective’ if
the point estimate suggests the treatment is expected
to be worse than the comparator and the 95% CrI does
not include 0 or 1 [37].
Results
Literature search
The study selection process is summarised in Figure 2.
The database searches performed in June 2013, without
restriction on publication year, identified 7,309 citations
of which 1,635 were excluded based on duplication elim-
ination. The remaining 5,674 were screened using the
population, intervention, comparators, outcomes, and
study design (PICOS) criteria and 5,249 were excluded
due to interventions not of interest (37%), study design
(33%), patient population (20%), and comparators (10%).
For the 425 included abstracts, full text publications
were retrieved and screened, with 245 being excluded
due to outcomes (22%), interventions (14%), compara-
tors (10%), study design (8%), and patient population
(2%). A number of pooled analyses (n = 29), systematic
literature reviews (SLRs), and (network) meta-analyses
of interest (n = 5) were identified and separated from the
main base of evidence. Pooled analyses of RCTs were
screened for studies not reported elsewhere. One pooled
Figure 2 Study selection flow chart.
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pendent studies) was identified and added to the evi-
dence base [38]. The SLRs and NMAs were reviewed to
validate the results of the selection process, but no fur-
ther relevant studies were identified [12,13,20,39,40]. Fi-
nally, 180 publications, covering 176 individual trials
involving 146,524 patients, were identified during the re-
view process and included in the NMA (see Additional
file 3 for a complete list of identified studies). Of these,
154 reported relevant efficacy, safety, and tolerability
outcomes, while the remaining 26 reported data on
safety and/or tolerability outcomes only. Publications
covering more than one study were extracted as separate
studies, assuming separate randomization schedules
were used for each study. Multiple publications covering
a single study were grouped together and extracted as
one study.
Study and patient characteristics
The majority of studies included patients with OA (n =
124) and a smaller number of studies investigated an RA
population (n = 38) or a combined OA/RA population
(n = 14). Most studies reported a randomised (n = 174),
double-blind (n = 160), and multicentre study design
(n = 128). Two non-randomised studies in which patients
served as their own control were included [41,42]. Studies
supporting a crossover design, in which patients switchedfrom placebo to active treatment or different dosages of
the active substance were included. However, if no wash-
out period between crossover was observed, data on effi-
cacy and safety outcomes after crossover were not used.
Overall, the 176 studies included 146,524 patients assigned
to one of the interventions of interest, acetaminophen, or
placebo. The size of the studies varied, with the number of
patients randomised to each treatment ranging from 12
[42] to 6,769 [43]. The trial duration was ranging from 2
to 104 weeks, while most studies lasted 12 weeks (n = 56)
or 6 weeks (n = 31). Long follow-up periods were mainly
observed in studies investigating the safety of NSAIDs and
COXIBs [43-46]. Ninety-five studies were placebo con-
trolled while 80 studies compared active treatments only.
Nineteen studies allowed the use of gastro-protective
agents during the study, if needed by patients, and 38
studies specifically prohibited their use. Aspirin use was
allowed during 66 trials at the discretion of the study in-
vestigators, while relevant information was missing for 64
studies. An overview of study design characteristics of in-
cluded studies is available in Additional file 4.
The age of the enrolled patients ranged from 17 to
75 years. Most studies included a predominantly female
population and two included women only [47,48]. Disease
duration ranged between 1 and 21 years. Information on
underlying risk factors that could act as potential treat-
ment effect modifiers was poorly reported. Eighteen
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sion, mostly recent safety studies with a special interest in
CV risk associated with NSAIDs and COXIBs. Fewer
studies reported on the percentage of smokers (n = 11),
while more information was available on risk factors asso-
ciated with GI safety, such as history of GI ulcer. Overall,
96 studies excluded patients with a history of GI problems,
including active GI ulcer at the screening visit or an ulcer
history within 1 to 6 months before enrolment. Details on
the patient characteristics of included studies are provided
in Additional file 5.
Based on the study design and patient characteristics
summarised above, and despite some differences, all 176
studies were considered to be comparable and all studies
reporting efficacy and/or tolerability outcomes were in-
cluded in the analyses. The number of events for safety
outcomes in the placebo arms of the studies was limited,
with only three APTC events in 630 pyrs of follow-up,
four major CV events in 727 pyrs of follow-up, and one
major GI event in 548 pyrs of follow-up. Although the
incidence of these rare serious events in the placebo
arms is expected to be low (especially in studies with
relatively short follow-up), this can introduce bias in the
analysis [35,36]. For this reason, data were synthesized
only if the sum of events per treatment across all in-
cluded trials in the network was at least 50. As a result,
the placebo and acetaminophen arms were not included
in the safety analyses networks. Three-arm studies com-
prising of two active treatment arms and one placebo
arm were included in the evidence base, excluding data
from the placebo arm. Furthermore, trials with zero
events in all arms do not contribute to the evidence on
the treatment effect and were thus excluded [32].
Efficacy and safety outcomes
The network diagrams, based on all studies included in
the NMA, are presented in Figures 3 (efficacy outcomes)
and 4 (safety outcomes). Because not all studies provide
data on each outcome, the network diagrams depictingFigure 3 Evidence network for efficacy outcomes.the available evidence per outcome are presented in
Additional file 6. The individual study results used for
the analyses are presented in Additional file 2.
Efficacy data were synthesized in a base case NMA
and seven scenario analyses, listed below. The base
case analysis estimated the relative efficacy of the in-
terventions of interest with the maximum dose allowed
in OA. Thus, for the base case, diclofenac 150 mg/day
was compared to naproxen 1,000 mg/day, ibuprofen
2,400 mg/day, celecoxib 200 mg/day, and etoricoxib
60 mg/day. Next, a number of scenario analyses were
performed:
1. Comparative efficacy of a lower diclofenac dose of
100 mg/day, versus the interventions of interest with
the maximum dosage allowed in OA
2. Comparative efficacy of 150 mg/day diclofenac
versus interventions of interest with the maximum
dosage allowed in RA (celecoxib 400 mg/day and
etoricoxib 90 mg/day)
3. Comparative efficacy of 100 mg/day diclofenac
versus interventions of interest with the maximum
dosage allowed in RA (celecoxib 400 mg/day and
etoricoxib 90 mg/day)
4. Combining all doses of NSAIDs and COXIBs in OA
and RA into a dose range, namely: diclofenac 75 to
150 mg/day, naproxen 500 to 1,000 mg/day,
ibuprofen 1,200 to 2,400 mg/day, celecoxib 100 to
400 mg/day, and etoricoxib 30 to 90 mg/day
5. Combining VAS and Likert scales using effect sizes,
as described in the Methods section
6. Including studies with at least 100 patients in each
treatment arm (data available in Additional file 7)
7. Including only studies recruiting patients after 1999,
as a proxy for improved study design according to
current standards (data available in Additional file 7).
Majority of safety outcomes (>80%) were reported
in trials involving a COXIB or high-dose tNSAID
Figure 4 Evidence network for safety outcomes.
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proxen 1,000 mg/day). Therefore, for the safety and tol-
erability outcomes, all available data were pooled and a
comparative analysis was conducted.
The results of the NMA on efficacy outcomes, as
ΔCFB with the corresponding 95% CrI for all treatments
versus diclofenac are presented in Figures 4 and 5 for
the 150 mg/day and 100 mg/day doses of diclofenac, re-
spectively. Results for scenario analyses described above
are presented in Additional file 7. The safety and toler-
ability NMA results, as RRs, are presented in Figure 6
together with their 95% CrI.
Efficacy
The relative efficacies versus placebo of all included
drugs at their maximum recommended doses for OA
(diclofenac 150 mg/day, celecoxib 200 mg/day, naproxen
1,000 mg/day, etorixocib 60 mg/day, ibuprofen 2,400
mg/day, and acetaminophen 4,000 mg/day) were evaluated
(Table 1). On all efficacy outcomes, all drugs were more
efficacious than placebo, with one exception: for physical
functioning measured with VAS at 12 weeks, the probabil-
ity of acetaminophen being better than placebo was
only 25%.
The relative efficacy of diclofenac versus the other in-
cluded drugs on pain, physical functioning, and PGA is
described below.
Pain
Data on pain measured by VAS were reported in 60
studies at 6 weeks and in 36 studies at 12 weeks. No
data were available for diclofenac 150 mg/day measured
on a Likert scale at 12 weeks and for diclofenac 100 mg/
day measured on a Likert scale at 6 weeks.
Diclofenac 150 mg/day demonstrated better results
(is likely to be more efficacious) in pain relief on VAScompared to all other treatments in both time points
(probability of being better, that is more efficacious,
treatment >85% in all pairwise comparisons), with the
exception of etoricoxib at 6 weeks (Pr (diclofenac being
better) = 52%). At 6 weeks, the ΔCFB compared to cel-
ecoxib 200 mg/day was −4.7 (95% CrI −8.0, −1.4), ver-
sus naproxen 1,000 mg/day was −3.4 (−7.0, 0), versus
etoricoxib 60 mg/day was −0.1 (−4.3, 4.0), and versus
ibuprofen 2,400 mg/day was −3.2 (−7.9, 1.5). Differ-
ences were similar at 12 weeks, although improved ver-
sus etoricoxib (ΔCFB −3.3 (−9.1, 2.5)). Favourable
results were obtained for pain measured by a Likert
scale versus celecoxib (−0.4 (−1.0, 0.2)) and similar
versus naproxen (0.1 (−0.8, 1.1)) (Figure 5).
Diclofenac 100 mg/day was comparable to all inter-
ventions, both at 6 and 12 weeks on a VAS scale
(Figure 6). Pain Likert at 12 weeks showed a favourable
result for diclofenac 100 mg/day compared to cele-
coxib (ΔCFB −1.1 (95% CrI −2.0, −0.2)) and naproxen
(ΔCFB −1.1 (95% CrI −2.0, −0.2)).
Physical functioning
Physical functioning measured by VAS was reported in
27 studies at 6 weeks and 16 studies at 12 weeks. Fewer
studies reported data on a Likert scale; seven studies re-
ported 6-week data and eight studies provided data on
12 weeks.
Diclofenac 150 mg/day showed comparable efficacy on
physical functioning (VAS) with celecoxib (6 weeks:
ΔCFB 0.2 (−4.1, 4.6); 12 weeks: ΔCFB 2.3 (−5.7, 10.5))
and ibuprofen (6 weeks: ΔCFB 1.2 (−4.5, 6.9); 12 weeks:
ΔCFB 3.3 (−5.9, 12.3)), while there was a trend in favour
of naproxen and etoricoxib (Figure 5). When physical
functioning was measured on a Likert scale at 6 weeks,
diclofenac 150 mg/day was likely to be more effective
compared to celecoxib (ΔCFB −2.2 (−4.5, 0.2)) and more
Figure 5 Forest plots of relative efficacy of diclofenac 150 mg/day.
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data were available at 12 weeks.
Data for diclofenac 100 mg/day were only available
for physical functioning VAS at 6 weeks and Likert at
12 weeks (Figure 6). In both cases, diclofenac
100 mg/day was likely to be more efficacious (Pr
(diclofenac being better) >85%) than the rest of the
treatments.Patient global assessment
There were 44 studies that provided data on PGA mea-
sured by a VAS scale at 6 (24 studies) and 12 (20 studies)
weeks, respectively. Data from Likert scale measurements
were provided in 14 studies at 6 weeks and 13 studies at
12 weeks. For both diclofenac 150 and 100 mg/day, only
one study provided data on PGA VAS at 6 weeks. No data
were available for diclofenac 150 mg/day PGA VAS and
Figure 6 Forest plots of relative efficacy of diclofenac 100 mg/day.
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nac 100 mg/day PGA VAS. Likert data were unavailable
for diclofenac 100 mg/day at 6 weeks.
When measured on a VAS scale at 6 weeks, the PGA
results for diclofenac 150 mg/day are comparable to cel-
ecoxib (ΔCFB −5.7 (−16.1, 4.7)), naproxen (ΔCFB −6.3
(−17.1, 4.4)), etoricoxib (−5.9 (−18.1, 6.0)), and ibuprofen
(−3.7 (−14.7, 7.4)) (Figure 5). The results are similar
when measured in Likert scale, with diclofenac being
comparable to celecoxib (ΔCFB −0.3 (−0.7, 0.2)) and na-
proxen (ΔCFB −0.1 (−0.1, 0.4)). No data were available
for diclofenac 150 mg/day at 12 weeks.
The results for diclofenac 100 mg/day demonstrated
comparable efficacy in terms of PGA VAS at 6 and12 weeks with etoricoxib 60 mg/day, while it was likely to
be more efficacious (Pr (diclofenac being better) >85%)
versus all other treatments.
Scenario analyses
A number of scenario analyses on the efficacy outcomes
were performed to test the validity of the results pre-
sented above. Comparing diclofenac 150 mg/day or
100 mg/day to the maximum dosages of etoricoxib
(90 mg/day) and celecoxib (400 mg/day) allowed in RA
did not change the conclusions. Neither did combining all
doses into a single dose range for each intervention. Even
though a substantial part of the studies identified was rela-
tively old or small, including only recent studies or large
Table 1 Relative efficacy versus placebo




















































































































































>99% NA NA −0.4
(−0.8; 0.0)
98% NA NA
Pain VAS, PF VAS, and PGA VAS are in mm. Pain Likert scale runs from 0 to 20, PF Likert scale runs from 0 to 68, PGA Likert scale runs from 0 to 5. CFB, change from baseline; CrI, credible interval; VAS, visual analogue















van Walsem et al. Arthritis Research & Therapy  (2015) 17:66 Page 11 of 18studies in the analysis did not influence the relative effi-
cacy of diclofenac compared to other NSAIDs. Lastly,
combining different outcome assessment tools, that is
VAS and Likert scales, resulted in similar conclusions on
efficacy as the base case analysis. Results of all scenario
analyses are presented in Table 2 and Additional file 7.
Safety
The safety results presented below were based on all
available data for the doses (that is, diclofenac 75 to
200 mg/day, naproxen 500 to 1,500 mg/day, ibuprofen
1,200 to 2,400 mg/day, celecoxib 100 to 800 mg/day, or
etoricoxib 30 to 90 mg/day).
APTC
Data on APTC events were reported in 22 studies. Of
these, 13 studies were included in the analyses after ex-
clusion of the placebo arms. Most studies reported data
for the two COXIBs (seven) and diclofenac (seven). Five
studies provided data for ibuprofen and only two studies
reported APTC events for naproxen. The longest avail-
able follow-up was for diclofenac and etoricoxib (41,225
and 40,578 person years, respectively), with over 96%
originating from the MEDAL program. Diclofenac was
associated with a similar risk of an APTC event as all
other interventions, with an RR of 1.1 (0.7, 1.8) versus
celecoxib, 0.9 (0.4, 2.0) versus naproxen, 1.0 (0.9, 1.2)
versus etoricoxib, and 0.9 (0.5, 1.6) versus ibuprofen.
Major CV events
Twenty-six studies provided data on major CV events,
of which 15 were included in the NMA. Naturally, all
studies reporting APTC events were included in this
analysis and two additional studies reporting major CV
events for naproxen, etoricoxib, and ibuprofen were
identified [49,50]. Etoricoxib studies provided the longest
follow-up (26,547 pyrs), with most of the data coming
from the MEDAL program (>97% of pyrs). As demon-
strated in Figure 7, diclofenac was associated with a
similar risk of major CV events as all other interven-
tions, with an RR of 1.2 (0.8, 1.8) versus celecoxib, 0.9
(0.4, 1.9) versus naproxen, 1.1 (0.9, 1.3) versus etori-
coxib, and 1.1 (0.7, 1.9) versus ibuprofen. The probability
of diclofenac being a safer treatment (that is, reducing
the number of events) was low (<25%) for all pairwise
comparisons, with the exception of naproxen (62%).
Major upper GI events
Major upper GI events were reported in 29 studies. The
analysis included 20 studies comparing active treatment
arms. Most data were available for celecoxib and na-
proxen, with 10 studies reporting for each treatment.
However, the longest follow-up was available for diclofe-
nac (27,300 person years, >90% from MEDAL program).Diclofenac was associated with a lower risk for major
upper GI events than both naproxen and ibuprofen, with
an RR of 0.3 (0.2, 0.6) versus naproxen and 0.5 (0.3, 0.9)
versus ibuprofen. Diclofenac was associated with a com-
parable risk of major upper GI events compared to cele-
coxib (RR 1.4 (0.8, 2.3)) and higher compared to
etoricoxib (RR 1.5 (1.3, 1.9)).
Tolerability
The analysis of tolerability outcomes was based on all
available data for the dose ranges of interest (diclofenac
75 to 200 mg/day, naproxen 500 to 1,500 mg/day, ibu-
profen 1,200 to 2,400 mg/day, celecoxib 100 to 800 mg/
day, or etoricoxib 30 to 90 mg/day).
Withdrawal due to any reason
The number of patients withdrawing for any reason was
reported in 96 studies. As demonstrated in Figure 7, diclo-
fenac was associated with a lower risk of withdrawal due
to any reason than placebo, ibuprofen, and acetamino-
phen, with an RR of 0.7 (0.6, 0.8), 0.7 (0.6, 0.9) and 0.8
(0.6, 1.0), respectively. The risk was similar for diclofenac
compared to celecoxib and naproxen, with an RR of 1.1
(1.0, 1.3) and 1.0 (0.8, 1.2), respectively. Diclofenac was as-
sociated with a higher risk of withdrawal compared to
etoricoxib, with an RR of 1.2 (1.0, 1.5) (Figure 7).
Withdrawal due to adverse events
Patients withdrawing because of adverse events were re-
ported in 105 studies. Diclofenac was comparable to na-
proxen (RR 1.1 (0.9, 1.4)), ibuprofen (0.9 (0.7, 1.2)), and
acetaminophen (0.9 (0.6, 1.4)). The risk was higher for
diclofenac compared to placebo (RR 1.6 (1.3, 1.9)), cele-
coxib (1.4 (1.2, 1.8)), and etoricoxib (1.7 (1.4, 2.2))
(Figure 7).
Withdrawal due to lack of efficacy
Patients withdrawing because of lack of efficacy were re-
ported in 89 studies. Diclofenac was associated with a
lower risk of withdrawals due to lack of efficacy com-
pared to placebo (RR 0.4 (0.3, 0.4)), celecoxib (0.8 (0.7,
1.0)), ibuprofen (0.7 (0.5, 0.9)), and acetaminophen (0.6
(0.4, 0.8)), while the risk was comparable to that of na-
proxen (0.9 (0.7, 1.1)) and etoricoxib (0.9 (0.7, 1.1))
(Figure 7).
The results of the key benefits and risks for diclofenac
150 mg/day versus the other treatments of interest are
summarised together in Table 3.
Discussion
This study is novel in that a range of different outcomes
were brought together, including efficacy (relief of pain,
physical functioning, PGA), tolerability (withdrawals), and
most commonly studied risks for NSAIDs (GI and CV).
Table 2 Scenario analyses on relative efficacy of diclofenac





























−13.7 (−16.9; −10.5) >99% −4.9 (−8.3; 1.4) >99% −3.1 (−7.1; 0.9) 94% 1.6 (−2.5; 5.6) 23% −1.3 (−6.7; 4.1) 68% −9.5 (−14.8; −4.1) >99%
Pain VAS
12 weeks
−10.1 (−13.2; −7.0) >99% −2.6 (−5.8; 0.5) 95% −0.9 (−4.2; 2.3) 70% 0.4 (−3.4; 4.0) 42% −1.6 (−5.8; 2.6) 77% −7.1 (−16.0; 1.7) 94%
Pain Likert
6 weeks
−1.8 (−2.3; −1.2) >99% −0.4 (−1.0; 0.2) 90% −0.3 (−1.1; 0.5) 77% NA NA NA NA NA NA
Pain Likert
12 weeks
−2.3 (−3.4; −1.2) >99% −1.2 (−2.3; 0.0) 98% −1.1 (−2.2; 0.0) 97% NA NA NA NA NA NA
PF VAS
6 weeks
−10.0 (−15.8; −4.4) >99% −1.2 (−7.3; 4.6) 66% 0.8 (−5.4; 6.7) 40% 1.2 (−4.4; 6.5) 33% −1.0 (−7.6; 5.3) 63% −6.7 (−15.1; 1.2) 95%
PF VAS
12 weeks
−4.5 (−11.9; 2.8) 89% 2.3 (−5.3; 10.0) 27% 5.9 (−1.9; 13.6) 7% 5.3 (−2.4; 13.0) 9% 3.1 (−5.3; 11.4) 23% −7.1 (−14.2; 0.1) 97%
PF Likert
6 weeks
−6.7 (−9.1; −4.4) >99% −2.2 (−4.5; 0.2) 96% −3.2 (−6.2; −0.2) 98% NA NA NA NA NA NA
PF Likert
12 weeks
−7.7 (−10.7; −4.7) >99% −3.8 (−6.9; −0.7) >99% −3.6 (−6.7; −0.5) 99% NA NA NA NA NA NA
PGA VAS
6 weeks
−16.6 (−24.3; −9.0) >99% −7.1 (−15.1; 0.8) 96% −7.0 (−15.3; 1.3) 95% −4.3 (−12.4; 3.8) 85% −5.3 (−13.9; 3.3) 89% NA NA
PGA VAS
12 weeks
−14.1 (−21.4; −6.8) >99% −6.6 (−14.1; 0.9) 96% −4.6 (−12.4; 3.0) 89% −2.4 (−10.0; 5.2) 74% −5.5 (−14.1; 3.1) 90% NA NA
PGA Likert
6 weeks
−0.5 (−0.7; −0.3) >99% −0.2 (−0.4; −0.1) >99% −0.1 (−0.2; 0.1) 76% NA NA NA NA NA NA
PGA Likert
12 weeks



























Pain 6 weeks −0.7 (−0.9; −0.4) >99% −0.3 (−0.5; 0.0) 98% −0.2 (−0.5; 0.1) 92% 0.0 (−0.3; 0.3) 54% −0.1 (−0.4; 0.2) 75% −0.5 (−0.8; −0.1) >99%
Pain 12 weeks −0.5 (−0.7; −0.3) >99% −0.2 (−0.4; 0.0) 98% −0.2 (−0.4; 0.0) 95% −0.1 (−0.3; 0.1) 70% −0.2 (−0.4; 0.1) 94% −0.4 (−0.8; 0.1) 93%
PF 6 weeks −0.5 (−0.6; −0.3) >99% −0.1 (−0.3; 0.1) 87% 0.0 (−0.2; 0.2) 51% 0.0 (−0.2; 0.2) 51% −0.1 (−0.3; 0.1) 83% −0.3 (−0.5; 0.0) 98%
PF 12 weeks −0.4 (−0.9; 0.2) 90% −0.1 (−0.6; 0.5) 60% 0.1 (−0.5; 0.6) 42% 0.0 (−0.5; 0.6) 44% 0.0 (−0.6; 0.5) 55% −0.6 (−1.1; 0.0) 98%
PGA 6 weeks −0.8 (−0.9; −0.6) >99% −0.2 (−0.4; −0.1) >99% −0.3 (−0.5; −0.1) >99% −0.2 (−0.4; −0.1) >99% −0.4 (−0.6; −0.2) >99% NA NA
PGA 12 weeks NA NA NA NA NA NA NA NA NA NA NA NA
Pain VAS, PF VAS, and PGA VAS are in mm. Pain Likert scale runs from 0 to 20, PF Likert scale runs from 0 to 68, and PGA Likert scale runs from 0 to 5. CFB, change from baseline; CrI, credible interval; VAS, visual
analogue scale; PF, physical functioning; PGA, patient global assessment; DCF, diclofenac; NA, data not available.
Scenario 4: combining all doses of NSAIDs and COXIBs in OA and RA into a dose range, namely: diclofenac 75 to 150 mg/day, naproxen 500 to 1,000 mg/day, ibuprofen 1,200 to 2,400 mg/day, celecoxib 100 to















Figure 7 Forest plots of safety and tolerability outcomes (pooled doses).
van Walsem et al. Arthritis Research & Therapy  (2015) 17:66 Page 13 of 18Also, the comparison of various benefits and risks was
undertaken in a rather homogenous population (arthritis
patients) in comparison to previously published meta-
analyses of various safety outcomes, which included
patients with entirely different underlying conditions, for
example Alzheimer’s disease, adenomatous polyps, and
others [20,21]. This is in line with the benefit and risk
evaluation done for underlying disease conditions in clin-
ical practice and the fact that treatment decisions are
dependent upon the defined patient circumstances.The objective was to assess the efficacy, safety, and toler-
ability of diclofenac compared to ibuprofen, naproxen, cel-
ecoxib, and etoricoxib in patients with pain caused by OA
or RA. The analysis was based on RCTs published in peer-
reviewed journals. The relevant studies were obtained by
means of an SLR and synthesized using a Bayesian NMA,
with 176 studies (146,524 patients) providing efficacy,
safety, or tolerability data. High-quality SLRs and NMAs
were reviewed to validate the results of the selection
process, but no further relevant studies were identified.
Table 3 Relative benefits and risks of diclofenac
Outcome Unit Assessment time point Placebo Celecoxib Naproxen Etoricoxib Ibuprofen Acetaminophen
Benefits Pain (VAS) ΔCFB (mm) 6 weeks −13.5 (−16.7, −10.4) −4.7 (−8.0, −1.4) −3.4 (−7.0, 0.1) −0.1 (−4.3, 4.0) −3.2 (−7.9, 1.5) −9.1 (−13.5, −4.7)
ΔCFB (mm) 12 weeks −12.3 (−17.3, −7.4) −5.1 (−10.2, −0.1) −3.3 (−8.6, 1.8) −3.3 (−9.1, 2.5) −4.5 (−11.5, 2.4) −8.0 (−16.6, 0.5)
Physical functioning (VAS) ΔCFB (mm) 6 weeks −7.7 (−11.9, −3.4) 0.2 (−4.1, 4.6) 2.8 (−1.7, 7.4) 2.4 (−2.4, 7.3) 1.2 (−4.5, 6.9) −5.4 (−12.4, 1.8)
ΔCFB (mm) 12 weeks −4.5 (−12.4, 3.1) 2.3 (−5.7, 10.5) 6.0 (−2.2, 14.1) 5.8 (−2.9, 14.3) 3.3 (−5.9, 12.3) −7.2 (−14.5, 0.3)
PGA VAS ΔCFB (mm) 6 weeks −15.3 (−25.4, −5.2) −5.7 (−16.1, 4.7) −6.3 (−17.1, 4.5) −5.9 (−18.0, 6.0) −3.7 (−14.7, 7.4) NA
Risks APTC Rate ratio Duration of study NA 1.1 (0.7, 1.8) 0.9 (0.4, 2.0) 1.0 (0.9, 1.2) 0.9 (0.5, 1.6) NA
Major CV event Rate ratio Duration of study NA 1.2 (0.8, 1.8) 0.9 (0.4, 1.9) 1.1 (0.9, 1.3) 1.1 (0.7, 1.9) NA
Major GI event Rate ratio Duration of study NA 1.4 (0.8, 2.3) 0.3 (0.2, 0.6) 1.5 (1.3, 1.9) 0.5 (0.3, 0.9) NA
Withdrawal due to any reason Rate ratio Duration of study 0.7 (0.6, 0.8) 1.1 (1.0, 1.3) 1.0 (0.8, 1.2) 1.2 (1.0, 1.5) 0.7 (0.6, 0.9) 0.8 (0.6, 1.0)
Withdrawal due to adverse events Rate ratio Duration of study 1.6 (1.3, 1.9) 1.4 (1.2, 1.8) 1.1 (0.9, 1.4) 1.7 (1.3, 2.2) 0.9 (0.7, 1.2) 0.9 (0.6, 1.4)
Withdrawal due to lack of efficacy Rate ratio Duration of study 0.4 (0.3, 0.4) 0.8 (0.7, 1.0) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 0.7 (0.5, 0.9) 0.6 (0.4, 0.8)
Mean and 95% credible intervals are presented; negative ΔCFB and rate ratios <1 favour diclofenac. Benefits were assessed using diclofenac 150 mg/day, naproxen 1,000 mg/day, ibuprofen 2,400 mg/day, celecoxib
200 mg/day, and etoricoxib 60 mg/day. Risks were assessed using dose ranges of the interventions of interest (diclofenac 75 to 200 mg/day, naproxen 500 to 1,500 mg/day, ibuprofen 1,200 to 2,400 mg/day, celecoxib
















van Walsem et al. Arthritis Research & Therapy  (2015) 17:66 Page 15 of 18The efficacy analysis was based on the labelled doses
for treatment of OA and RA for each treatment option.
All drugs were significantly better than placebo for all
efficacy outcomes. Diclofenac 150 mg/day was likely to
be more effective in alleviating pain than celecoxib and
ibuprofen (both scales: VAS and Likert), naproxen
(VAS), and etoricoxib (VAS 12 weeks). Its efficacy was
similar compared to etoricoxib (VAS) and naproxen
(Likert) at 6 weeks. Diclofenac 100 mg/day was compar-
able to all other interventions for pain relief. For physical
functioning, diclofenac 150 mg/day seemed to be similar
to celecoxib and ibuprofen on VAS at 6 and 12 weeks
and seemed favourable to celecoxib and naproxen on
Likert at 6 weeks. Diclofenac 100 mg/day was compar-
able to the rest of the treatments for physical function-
ing VAS at 6 weeks and Likert at 12 weeks, no other
data were available. Although only a small number
of studies provided data for PGA, diclofenac was com-
parable to all treatments for the outcomes and time
points available. Various scenario analyses were in line
with the base case and did not change the main findings.
The safety analysis was based on pooling of events
from data available on all doses identified in the
evidence base for each treatment because of the low
frequency of observed events. All active treatments
demonstrated similar incidence of CV outcomes (APTC
and major CV). Diclofenac was associated with a lower
incidence of major upper GI events compared to naproxen
and ibuprofen, comparable to celecoxib, and higher
than etoricoxib.
Risk of withdrawals due to any cause was lower for
diclofenac than ibuprofen, similar to naproxen and cele-
coxib, and higher than etoricoxib. Patients treated with
diclofenac had a similar risk of withdrawals due to an
adverse event to ibuprofen and naproxen and higher
risk compared to celecoxib and etoricoxib. The risk of
withdrawal due to lack of efficacy for diclofenac was
lower than ibuprofen and celecoxib and similar to etori-
coxib and naproxen.
The results presented in this study are in agreement
with the findings of other Bayesian NMAs of RCTs on
the efficacy and safety of COXIBs and NSAIDs pub-
lished during the last 2 years [20,21,51]. Stam et al. com-
pared the efficacy of diclofenac, ibuprofen, naproxen,
celecoxib, etoricoxib, and lumiracoxib in OA [51]. Their
main findings are in agreement with our results: etori-
coxib had a low probability to provide a small improve-
ment in pain relief and physical functioning over
diclofenac. For PGA, Stam et al. report similar results
versus placebo for diclofenac and etoricoxib, while our
results are in favour of diclofenac [51]. This could be a
result of the differences in the evidence base and
methods used (for example all time points were pooled
together in Stam et al.).Trelle at al. conducted an NMA on the CV safety of
the five NSAIDs included in our study plus rofecoxib
and lumiracoxib [20]. A much broader patient popula-
tion (only cancer patients were excluded) and trials
with at least 100 pyrs of follow-up per arm were in-
cluded, leading to a different evidence base compared
to our study. Despite this, a similar CV safety profile
was reported for diclofenac compared to etoricoxib for
all events (RR close to 1), which was confirmed in our
findings for major CV and APTC. For celecoxib and
ibuprofen, the APTC results versus diclofenac are in
agreement with ours, while it is not easy to compare
the rest of the outcomes as the mean RR varies per in-
dividual CV event. For naproxen, they report either
similar results (MI) versus diclofenac or in favour or
naproxen (CV death), while in our analysis a mean RR
of 0.9 in favour of diclofenac with wide CrIs (0.4, 1.9)
were estimated for the major CV events. This differ-
ence could be due to the fact that only an inflammatory
arthritis population was included in our study.
The CNT Collaboration conducted a meta-analysis of
safety outcomes for six COXIBs (celecoxib, etoricoxib,
rofecoxib, valdecoxib, lumiracoxib, and GW403681)
compared to traditional NSAIDs, including diclofenac
[21]. The analysis was based on aggregated and individ-
ual patient data from 754 studies, any of which were
small and of short duration. Comparing the (pooled)
COXIBs to diclofenac, the RR for major vascular events
was 0.97 (95% CI 0.84 to 1.12), which is in line with the
results of our analysis. Their results are similar for upper
GI complications, with an RR of 0.94 (95% CI 0.72 to
1.24) for all COXIBs pooled together; in our study,
diclofenac had a comparable profile to celecoxib and
etoricoxib demonstrated a better profile. This disagree-
ment could be explained by the difference in the evi-
dence base and the pooling of all COXIBs.
As for any NMA, inherent limitations are related to
the quality and availability of data, the potential for
within-study bias, and publication bias. Although the
studies included were of satisfactory quality, there are
limitations to the evidence base, mainly related to the
low number of events. A low number of events is limit-
ing the ability of a meta-analysis to detect differences be-
tween treatments and can eventually give misleading
results [35,36] (also supported by a pain trials simulation
study [52]). While we tried to overcome this problem by
limiting analyses for safety outcomes to where there
were at least 50 events per treatment arm, small differ-
ences should still be treated with caution. A publication
bias might occur, but we assume that this bias acts in
the same way across all the treatments; therefore, in the
NMA, the effect of this bias should be ameliorated for
the relative difference between comparators. To further
reduce the potential of a publication bias, our literature
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CNT Collaboration study [21].
Another potential limitation is that studies often use dif-
ferent methods for handling missing data due to dropouts,
including last observation carried forward, baseline obser-
vation carried forward, multiple imputation, available data,
and others. These differences can lead to differences in re-
ported outcomes. However, it has been established that in
the absence of a large excess of adverse event withdrawals
with active drug over placebo, an imputation method
makes little difference [53-56].
Furthermore, a low number of patients or shorter dur-
ation can lead to an overestimation of the treatment ef-
fect in pain studies and, particularly in OA, over 20%
overestimation has been reported by Nuesch et al. [57].
Some studies included in this NMA are reporting results
for a low number of patients, which may have an impact
on the estimation of the outcomes; however, only studies
with ≥4 weeks’ treatment duration were included. Vari-
ous scenario analyses including only studies with more
than 100 patients were conducted to validate the results,
which were not altered providing additional confidence
in the conclusions made.
It could be argued that small changes in pain scales
could not be clinically meaningful. However, small aver-
age changes on a VAS scale translates into substantial
gains in the percentage of people getting good, long-
term pain relief. Moore et al. reported that an average of
10 mm improvement in pain more than placebo equates
to almost one in two patients having substantial benefit
[58]. In this analysis, diclofenac 150 mg resulted in an
average 12.3 mm improvement over placebo at 12 weeks;
therefore, a significant proportion of patients would have
had benefit. This was further supported by improve-
ments observed in other benefit outcomes of physical
functioning and PGA. Because individual patient data
were not available in the publications reviewed, a limita-
tion of our analysis is that it does not report probability
of treatments achieving >30% or >50% improvement in
pain accepted as clinically meaningful. It is also import-
ant to note that general considerations for determining
clinically important differences have evolved rather re-
cently [59], and the conduct of most of the clinical stud-
ies precede this era. Clinically meaningful differences are
not uniformly reported or published. However, clinical
response to NSAIDs is highly variable and influenced by
a number of factors and is not just limited to the efficacy
of individual drugs. No meta-analysis or even a clinical
trial is an absolute predictor of meaningful clinical re-
sponse in the individual patient.
For patients with pain and inflammation, NSAIDs are
a recommended treatment option, and it is important to
find a balance between known benefits and risks. With
good pain relief also come significant improvements incomorbid symptoms like fatigue and depression and
large improvements in HRQoL and work [8]. Other
treatment alternatives for pain management also have
associated risks, for example acetaminophen is associ-
ated with liver toxicity and severe cutaneous reactions
[60]. Other treatment alternatives include opioids, which
could be highly addictive, for example in a cross-
sectional study of chronic pain patients, the prevalence
of addiction was 14% [61]. Restrictive use of NSAIDs
due to the decade-old debate on associated CV risks has
led to a drastic increase in opioid prescriptions drug
class use, associated with diversion, abuse, overdose, and
even deaths due to respiratory depression [62].
NSAIDs have been the cornerstone in pain manage-
ment for decades, and have a favourable benefit-risk pro-
file and attributes that distinguish them from other
available analgesics, also associated with some risks. Pa-
tients might be willing to accept risks associated with
NSAID treatment for their pain improvement, including
a small increase in the risk of serious events, for example
in exchange for 25-mm improvement on the VAS scale in
ambulatory pain, OA patients were willing to accept an in-
crease of 0.8% points (95% CI 0.4 to 1.4%) in MI risk
[63,64]. Risk tolerance is poorly understood and may vary
based upon the level of pain, the underlying indication,
and the effectiveness and risk associated with a given dose
of medication to alleviate painful, debilitating symptoms.
In clinical decision-making, the prescription of treat-
ment involves a trade-off between the expected benefit
of treatment and the potential of risk based on patient
circumstances. Focusing just on associated risks without
taking into consideration the benefits that NSAID treat-
ment can bring could lead to erroneous conclusions in
the holistic benefit-risk assessment for these drugs.
This study provides a benefit-risk assessment for a
comparative evaluation of the commonly used NSAIDs
that could be used to inform clinical practice.
Conclusions
All NSAIDs were shown to provide clinically meaning-
ful pain relief in patients with chronic arthritis and im-
prove physical function and well-being. The benefit-risk
profile of diclofenac was comparable to other treat-
ments used for pain relief in OA and RA. Both benefits
and risks vary across treatments and must be taken into
consideration while making decisions both by clinicians
and by regulators.
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